LVTX Annual SG&A
$12.73 M
-$1.40 M-9.90%
31 December 2023
Summary:
As of January 23, 2025, LVTX annual selling, general & administrative expenses is $12.73 million, with the most recent change of -$1.40 million (-9.90%) on December 31, 2023. During the last 3 years, it has risen by +$10.01 million (+368.04%). LVTX annual SG&A is now -9.90% below its all-time high of $14.12 million, reached on December 31, 2022.LVTX Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LVTX Quarterly SG&A
$2.79 M
-$240.00 K-7.93%
30 September 2024
Summary:
As of January 23, 2025, LVTX quarterly selling, general & administrative expenses is $2.79 million, with the most recent change of -$240.00 thousand (-7.93%) on September 30, 2024. Over the past year, it has dropped by -$73.00 thousand (-2.55%). LVTX quarterly SG&A is now -34.27% below its all-time high of $4.24 million, reached on March 31, 2022.LVTX Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LVTX TTM SG&A
-$622.20 M
-$27.02 M-4.54%
30 September 2024
Summary:
As of January 23, 2025, LVTX TTM selling, general & administrative expenses is -$622.20 million, with the most recent change of -$27.02 million (-4.54%) on September 30, 2024. Over the past year, it has dropped by -$636.22 million (-4536.68%). LVTX TTM SG&A is now -1763.66% below its all-time high of $14.94 million, reached on June 30, 2022.LVTX TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LVTX Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -9.9% | -2.5% | -4536.7% |
| 3 y3 years | +368.0% | -2.5% | -4536.7% |
| 5 y5 years | +929.6% | -2.5% | -4536.7% |
LVTX Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -9.9% | +5.9% | -34.3% | +22.1% | -139.0% | at low |
| 5 y | 5-year | -9.9% | +929.6% | -34.3% | +680.5% | -1763.7% | at low |
| alltime | all time | -9.9% | +929.6% | -34.3% | +680.5% | -1763.7% | at low |
LAVA Therapeutics NV Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $2.79 M(-7.9%) | $11.03 M(-0.7%) |
| June 2024 | - | $3.02 M(+3.1%) | $11.10 M(-5.7%) |
| Mar 2024 | - | $2.94 M(+28.7%) | $11.77 M(-7.5%) |
| Dec 2023 | $12.73 M(-9.9%) | $2.28 M(-20.2%) | $12.73 M(-9.3%) |
| Sept 2023 | - | $2.86 M(-22.7%) | $14.02 M(-1.9%) |
| June 2023 | - | $3.70 M(-5.0%) | $14.30 M(+3.8%) |
| Mar 2023 | - | $3.89 M(+8.7%) | $13.78 M(-2.5%) |
| Dec 2022 | $14.12 M | $3.58 M(+14.2%) | $14.12 M(-1.3%) |
| Sept 2022 | - | $3.13 M(-1.2%) | $14.31 M(-4.2%) |
| June 2022 | - | $3.17 M(-25.1%) | $14.94 M(+2.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | $4.24 M(+12.4%) | $14.53 M(+20.9%) |
| Dec 2021 | $12.02 M(+342.0%) | $3.77 M(+0.2%) | $12.02 M(+39.6%) |
| Sept 2021 | - | $3.76 M(+36.0%) | $8.61 M(+53.1%) |
| June 2021 | - | $2.76 M(+60.0%) | $5.62 M(+55.6%) |
| Mar 2021 | - | $1.73 M(+384.0%) | $3.61 M(+36.9%) |
| Dec 2020 | $2.72 M(+120.0%) | $356.80 K(-53.9%) | $2.64 M(+15.6%) |
| Sept 2020 | - | $773.70 K(+2.4%) | $2.28 M(+51.3%) |
| June 2020 | - | $755.80 K(+0.5%) | $1.51 M(+100.5%) |
| Mar 2020 | - | $752.20 K | $752.20 K |
| Dec 2019 | $1.24 M | - | - |
FAQ
- What is LAVA Therapeutics NV annual selling, general & administrative expenses?
- What is the all time high annual SG&A for LAVA Therapeutics NV?
- What is LAVA Therapeutics NV annual SG&A year-on-year change?
- What is LAVA Therapeutics NV quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for LAVA Therapeutics NV?
- What is LAVA Therapeutics NV quarterly SG&A year-on-year change?
- What is LAVA Therapeutics NV TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for LAVA Therapeutics NV?
- What is LAVA Therapeutics NV TTM SG&A year-on-year change?
What is LAVA Therapeutics NV annual selling, general & administrative expenses?
The current annual SG&A of LVTX is $12.73 M
What is the all time high annual SG&A for LAVA Therapeutics NV?
LAVA Therapeutics NV all-time high annual selling, general & administrative expenses is $14.12 M
What is LAVA Therapeutics NV annual SG&A year-on-year change?
Over the past year, LVTX annual selling, general & administrative expenses has changed by -$1.40 M (-9.90%)
What is LAVA Therapeutics NV quarterly selling, general & administrative expenses?
The current quarterly SG&A of LVTX is $2.79 M
What is the all time high quarterly SG&A for LAVA Therapeutics NV?
LAVA Therapeutics NV all-time high quarterly selling, general & administrative expenses is $4.24 M
What is LAVA Therapeutics NV quarterly SG&A year-on-year change?
Over the past year, LVTX quarterly selling, general & administrative expenses has changed by -$73.00 K (-2.55%)
What is LAVA Therapeutics NV TTM selling, general & administrative expenses?
The current TTM SG&A of LVTX is -$622.20 M
What is the all time high TTM SG&A for LAVA Therapeutics NV?
LAVA Therapeutics NV all-time high TTM selling, general & administrative expenses is $14.94 M
What is LAVA Therapeutics NV TTM SG&A year-on-year change?
Over the past year, LVTX TTM selling, general & administrative expenses has changed by -$636.22 M (-4536.68%)